AWHL — Aspira Women's Health Share Price
0.000.00%
Last trade - 00:00- $2.47m
- $2.82m
- $9.18m
- 27
- 51
- 13
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70773.91% | ||
| Return on Equity | n/a | ||
| Operating Margin | -177.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.65 | 6.81 | 8.18 | 9.15 | 9.18 | 24 | 32.66 | 15.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
Directors
- James Lafrance NEC (62)
- Valerie Palmieri PRE (59)
- Robert Beechey CFO (58)
- Mint Merchant GCN
- Veronica Jordan IND (70)
- Nicole Sandford IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 23rd, 2000
- Public Since
- September 29th, 2000
- No. of Shareholders
- 45
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 35,224,258
- Address
- 12117 Bee Caves Road Building Three, AUSTIN, 78738
- Web
- https://aspirawh.com/
- Phone
- +1 5125190400
- Auditors
- BDO USA, P.C.
Upcoming Events for AWHL
Q1 2025 Aspira Women's Health Inc Earnings Release
Q2 2025 Aspira Women's Health Inc Earnings Release
Similar to AWHL
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Aspira Women's Health share price?
As of Today at 19:23 UTC, shares in Aspira Women's Health are trading at $0.07. This share price information is delayed by 15 minutes.
How has the Aspira Women's Health share price performed this year?
Shares in Aspira Women's Health last closed at $0.07 and the price had moved by -97.82% over the past 365 days. In terms of relative price strength the Aspira Women's Health share price has underperformed the S&P500 Index by -97.98% over the past year.
What are the analyst and broker recommendations for Aspira Women's Health?
The overall consensus recommendation for Aspira Women's Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aspira Women's Health dividend yield?
Aspira Women's Health does not currently pay a dividend.
Does Aspira Women's Health pay a dividend?
Aspira Women's Health does not currently pay a dividend.
When does Aspira Women's Health next pay dividends?
Aspira Women's Health does not currently pay a dividend.
How do I buy Aspira Women's Health shares?
To buy shares in Aspira Women's Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aspira Women's Health?
As of the previous close price of $0.07, shares in Aspira Women's Health had a market capitalisation of $2.47m.
Where are Aspira Women's Health shares listed?
Here are the trading details for Aspira Women's Health:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AWHL
What kind of share is Aspira Women's Health?
Based on an overall assessment of its quality, value and momentum Aspira Women's Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aspira Women's Health share price forecast for 2025?
The analyst consensus target price for shares in Aspira Women's Health is $5.50. That is 7757.14% above the last closing price of $0.07.
Analysts covering Aspira Women's Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreWhat is the trend in the Aspira Women's Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aspira Women's Health. Over the past six months, its share price has underperformed the S&P500 Index by -92.2%.
As of the last closing price of $0.07, shares in Aspira Women's Health were trading -89.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aspira Women's Health PE Ratio?
The Aspira Women's Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aspira Women's Health?
Aspira Women's Health's management team is headed by:
- James Lafrance - NEC
- Valerie Palmieri - PRE
- Robert Beechey - CFO
- Mint Merchant - GCN
- Veronica Jordan - IND
- Nicole Sandford - IND